Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 7Pheochromocytoma 2Paraganglioma 2Gastro-enteropancreatic neuroendocrine tumor 2Vipoma 1Thymus Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms 1Meningioma 1Insulinoma 1Gastrinoma 1Carcinoma, Merkel Cell 1Carcinoid Tumor 1

Interventions

Temozolomide 2Leucovorin 2Fluorouracil 2Capecitabine 2veliparib 1pentetreotide 1Thalidomide 1Oxaliplatin 1Octreotide 1Irinotecan 1Bevacizumab 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Vipoma × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all
NCT04915144 2023-02-21

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

British Columbia Cancer Agency

Phase 2 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡